{name}
{subtitle}
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~25 mi. (Avellino, Italy, +115 more cities)
facility
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati
biomarker
ERBB2 Amplification, +7 more biomarkers
drug type
immunotherapy, +1 more type
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~25 mi. (Avellino, Italy, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~40 mi. (Rionero in Vulture, Italy, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
city
~40 mi. (Rionero in Vulture, Italy, +156 more cities)
facility
Irccs-Crob /Id# 170955
biomarker
IGH-CCND1 Fusion, +1 more biomarker
drug
dexamethasone, +1 more drug
drug type
chemotherapy, +1 more type
Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
city
~40 mi. (Rionero in Vulture, Italy, +120 more cities)
facility
IRCCS Centro di Riferimento Oncologico di Basilicata
biomarker
FGFR3 A391E, +9 more biomarkers
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~44 mi. (Napoli, Italy, +192 more cities)
facility
Istituto Nazionale Tumori IRCCS Fondazione Pascale
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~44 mi. (Napoli, Italy, +383 more cities)
facility
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type